1. Home
  2. IMNM vs ABCL Comparison

IMNM vs ABCL Comparison

Compare IMNM & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNM
  • ABCL
  • Stock Information
  • Founded
  • IMNM 2006
  • ABCL 2012
  • Country
  • IMNM United States
  • ABCL Canada
  • Employees
  • IMNM N/A
  • ABCL N/A
  • Industry
  • IMNM Medicinal Chemicals and Botanical Products
  • ABCL Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMNM Health Care
  • ABCL Health Care
  • Exchange
  • IMNM Nasdaq
  • ABCL Nasdaq
  • Market Cap
  • IMNM 945.8M
  • ABCL 1.1B
  • IPO Year
  • IMNM 2020
  • ABCL 2020
  • Fundamental
  • Price
  • IMNM $9.69
  • ABCL $4.55
  • Analyst Decision
  • IMNM Strong Buy
  • ABCL Strong Buy
  • Analyst Count
  • IMNM 8
  • ABCL 5
  • Target Price
  • IMNM $24.75
  • ABCL $8.00
  • AVG Volume (30 Days)
  • IMNM 756.6K
  • ABCL 4.1M
  • Earning Date
  • IMNM 08-06-2025
  • ABCL 11-03-2025
  • Dividend Yield
  • IMNM N/A
  • ABCL N/A
  • EPS Growth
  • IMNM N/A
  • ABCL N/A
  • EPS
  • IMNM N/A
  • ABCL N/A
  • Revenue
  • IMNM $12,589,000.00
  • ABCL $32,875,999.00
  • Revenue This Year
  • IMNM N/A
  • ABCL $15.60
  • Revenue Next Year
  • IMNM $154.73
  • ABCL $65.70
  • P/E Ratio
  • IMNM N/A
  • ABCL N/A
  • Revenue Growth
  • IMNM 16.74
  • ABCL N/A
  • 52 Week Low
  • IMNM $5.15
  • ABCL $1.89
  • 52 Week High
  • IMNM $16.73
  • ABCL $5.82
  • Technical
  • Relative Strength Index (RSI)
  • IMNM 48.73
  • ABCL 57.55
  • Support Level
  • IMNM $8.67
  • ABCL $4.09
  • Resistance Level
  • IMNM $9.71
  • ABCL $4.28
  • Average True Range (ATR)
  • IMNM 0.63
  • ABCL 0.24
  • MACD
  • IMNM -0.04
  • ABCL 0.03
  • Stochastic Oscillator
  • IMNM 51.64
  • ABCL 82.76

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: